NBTXR3 | Nano Publications

2018 – ASTRO – NBTXR3 Exploratory Dosimetric Study

Clinical Data NBTXR3, Congress Abstracts, STS

NBTXR3, injectable hafnium oxide nanoparticles, was designed to increase the energy deposit of the irradiation when activated by radiotherapy for the treatment of solid tumors. It is currently evaluated in a phase II/III clinical trial in soft tissue sarcoma (STS) [NCT02379845] of the extremity and trunk wall, to compare its efficacy when intratumorally injected and activated by radiotherapy versus radiotherapy alone. […]

2018 – ASTRO – NBTXR3 in solid tumors

Clinical Data NBTXR3, Congress Abstracts, Head & Neck, Liver, Rectum, STS

To improve radiotherapy (RT) in terms of tumor response and to reduce irradiation of healthy tissues, innovative therapeutic approaches are needed. In response, NBTXR3, injectable hafnium oxide nanoparticles, was developed for the treatment of solid tumors. Once injected intratumorally, NBTXR3 can deposit high energy within tumors only when activated by an ionizing radiation source, like current standard RTs. […]

2018 – ESMO – Phase II/III NBTXR3 in STS

Clinical Data NBTXR3, Congress Abstracts, STS

NBTXR3 is a first-in-class Hafnium-Oxide nanoparticle intratumorally (IT) injected. When activated by radiotherapy (RT), it allows for a higher energy deposit than RT alone, yielding an increased tumoral cell death. A phase I study in soft tissue sarcoma (STS) showed that a single NBTXR3 IT injection at 10% of the baseline tumor volume with preoperative RT was technically feasible with manageable toxicity and clinical activity was observed. […]

2018 – ASTRO 2018 – NBTXR3 in elderly HNSCC

Clinical Data NBTXR3, Congress Abstracts, Head & Neck

As the incidence of head and neck squamous cell carcinoma (HNSCC) increases with age, elderly patients represent 25% of the affected population with an expected increase in the next 20 years. Being more vulnerable to treatment-induced toxicities, the elderly cannot be treated like younger patients, hence requiring innovative therapies. […]

2018 – ASTRO 2018 – Phase III NBTXR3 in Soft Tissue Sarcoma

Clinical Data NBTXR3, Congress Abstracts, STS

A subset of soft tissue sarcoma (STS) patients achieve significant therapeutic benefit from preoperative radiotherapy (RT). Yet, this treatment paradigm may be associated with limited efficacy and increased toxicity, highlighting the necessity of novel multimodal therapies aimed at local control with few adverse events (AEs). NBTXR3 is a first-in-class Hafnium-Oxide nanoparticle. […]

2018-ASTRO 2018- NBTXR3 in liver cancers

Clinical Data NBTXR3, Congress Abstracts, Liver

Radiation oncology technological development is principally focused in improving the precision of radiotherapy (RT) and reducing unwanted irradiation to normal tissues. There is an unmet medical need into ameliorating the energy dose deposit within tumor cells without increasing the dose received by surrounding healthy tissues. […]

2018 – ESMO – NBTXR3 in HCC and Liver Metastasis

Clinical Data NBTXR3, Congress Abstracts, Head & Neck, Liver

For patients (pts) with hepatocellular carcinoma (HCC) or liver metastasis (liver mets), stereotactic body radiation therapy (SBRT) is a well-tolerated option. Yet, the risk of injury to normal tissues limits the ability to efficiently sterilize tumor cells. Thus, hafnium oxide nanoparticles, NBXTR3, were developed, which increase the interaction of radiotherapy energy dose deposition within tumor cells when activated by an ionizing energy source like SBRT. […]

2018 – ESMO 2018 – NBTXR3 in elderly HNSCC

Clinical Data NBTXR3, Congress Abstracts, Liver

Elderly patients (pts) with head and neck squamous cell carcinoma (HNSCC) represent 25% of the affected population. They are not always eligible to the same treatment of younger pts, thus require new therapies. NBTXR3, injectable hafnium oxide nanoparticles activated by radiotherapy (RT), was developed to increase the local deposit of energy within the tumor. […]

2018 – ESMO WGI – NBTXR3 in HCC and Liver Mets

Clinical Data NBTXR3, Congress Abstracts, Liver

Management of hepatocellular carcinoma (HCC) and liver metastasis (mets) requires complementary expertise of multiple specialties. Treatment decisions are increasingly complex and physicians must face a wide range of underlying liver dysfunctions and concomitant malignancies. Among available treatments, stereotactic body radiation therapy (SBRT) is well-tolerated. […]

2018 – ASCO – NBTXR3 in the treatment of liver cancer: a phase I/II trial

Clinical Data NBTXR3, Congress Abstracts, Liver

With recent advances in radiation delivery techniques, an increasing number of cancer patients undergo radiotherapy. However, due to the non-targeted nature of radiotherapy, doses are limited by potential toxicity to surrounding normal tissue. Thus, a major challenge remains to develop new strategies to improve the tumor selectivity of radiation therapy. […]